866-997-4948(US-Canada Toll Free)

Dapagliflozin (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 43 Pages


GlobalDatas pharmaceuticals report, Dapagliflozin (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Dapagliflozin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for theUS, EU5 and Japan (seven major markets)
  • Analysis and review of Dapagliflozin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Dapagliflozin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Dapagliflozin in the US, EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Dapagliflozin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Monotherapy 25
7.3.2 Combination Therapy 26
7.4 Approval of Dapagliflozin 28
7.5 Factors Affecting Sales of Dapagliflozin 28
7.5.1 First in Class SGLT-2 28
7.5.2 Results in Weight Loss 28
7.5.3 Secondary Benefits 28
7.5.4 Uncertainity over Safety profile 28
7.5.5 Increased Risk of Genital Infections 28
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Forecasts 30
7.7.1 Target Patient Pool for Dapagliflozin 30
7.7.2 Market Penetration 30
7.7.3 Dosing 30
7.7.4 Annual Cost of Therapy 30
7.7.5 Sales Projections of Dapagliflozin 31

8 Diabetes Market: Appendix 40
8.1 Market Definitions 40
8.2 List of Abberiviations 40
8.3 Research Methodology 40
8.3.1 Coverage 41
8.3.2 Secondary Research 41
8.3.3 Forecasting 41
8.3.4 Net Penetration of Drug 42
8.3.5 Net Annual Dosing 42
8.3.6 Annual Cost of Therapy 42
8.3.7 Primary Research 42
8.3.8 Expert Panels 42
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 43
8.7 Sources 43

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Results of 24-Week Placebo Controlled Trial of Dapagliflozin Used as Monotherapy 26
Table 10: Results of 24-Week Placebo Controlled Trials of Dapagliflozin in Combination Therapy with Metformin 27
Table 11: Drug Risk Benefit Score of Dapagliflozin 29
Table 12: Efficacy Comparison of Dapagliflozin with its Competitors 29
Table 13: Dapagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2012-2020 31
Table 14: Dapagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2012-2020 32
Table 15: Dapagliflozin, Type 2 Diabetes, the UK, Sales Forecasts ($m), 2012-2020 33
Table 16: Dapagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020 34
Table 17: Dapagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2020 35
Table 18: Dapagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2020 36
Table 19: Dapagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2012-2020 37
Table 20: Dapagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020 38

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Dapagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2012-2020 31
Figure 13: Dapagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2012-2020 32
Figure 14: Dapagliflozin, Type 2 Diabetes, the UK, Sales Forecasts ($m), 2012-2020 33
Figure 15: Dapagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020 34
Figure 16: Dapagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2020 35
Figure 17: Dapagliflozin Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2020 36
Figure 18: Dapagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2012-2020 37
Figure 19: Dapagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020 38
Figure 20: Dapagliflozin, Type 2 Diabetes, Global, Sales Distribution (%), 2020 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *